Quickly
Socially
Trending
Crypto
COVISHIELD
COVID-19 Vaccine Covishield, Developed by Oxford-AstraZeneca, Would be Sold to Govt For Rs 250 Per Dose, Says Adar Poonawalla
COVID-19 Vaccine Covishield May Get Emergency Use Authorisation From India in December 2020, Says Report
When Will COVID-19 Vaccine Covishield, Developed by Oxford-AstraZeneca, Be Available? Adar Poonawalla Responds
COVID-19 Vaccine Update: Mumbai’s KEM Hospital Gets Nod for Phase II and III Trials of Oxford Covishield Vaccine
COVID-19 Vaccine Update: Phase 3 Human Clinical Trial of Oxford Vaccine Covishield Begins in Pune
COVID-19 Vaccine Update: DCGI Directs Serum Institute to Suspend Any New Recruitment in Phase 2, 3 Clinical Trials of Oxford Candidate
COVID-19 Vaccine Update: Oxford's Coronavirus Vax May Be Ready by Year End In Spite of Pause in Clinical Trials, Says AstraZeneca CEO Pascal Soriot
COVID-19 Vaccine Update: Phase 3 Human Clinical Trial of Oxford Vaccine Covishield Begins in Pune
COVID-19 Vaccine Update: DCGI Directs Serum Institute to Suspend Any New Recruitment in Phase 2, 3 Clinical Trials of Oxford Candidate
COVID-19 Vaccine Update: Oxford's Coronavirus Vax May Be Ready by Year End In Spite of Pause in Clinical Trials, Says AstraZeneca CEO Pascal Soriot
COVID-19 Vaccine Update: Serum Institute of India Says Will Adhere to DCGI Instructions After Show Cause Notice Over Not Pausing Trial of Covishield Vaccine
COVID-19 Vaccine Update: DCGI Sends Show Cause Notice to Serum Institute of India for Not Pausing Trial of Covishield
Arvind Kejriwal Allows RT-PCR COVID-19 Tests Without Prescription In Delhi, Vaccine ‘Sputnik V’ To Be Tested In India, Says Russian Media
Health & Wellness
COVID-19 Vaccine Update: Oxford's Coronavirus Vax May Be Ready by Year End In Spite of Pause in Clinical Trials, Says AstraZeneca CEO Pascal Soriot
COVID-19 Vaccine Update: Serum Institute of India Says Will Adhere to DCGI Instructions After Show Cause Notice Over Not Pausing Trial of Covishield Vaccine
COVID-19 Vaccine Update: DCGI Sends Show Cause Notice to Serum Institute of India for Not Pausing Trial of Covishield
Arvind Kejriwal Allows RT-PCR COVID-19 Tests Without Prescription In Delhi, Vaccine ‘Sputnik V’ To Be Tested In India, Says Russian Media
COVID-19 Vaccine Update: Clinical Trials of Oxford's Covishield Will Continue in India, Says Serum Institute of India After AstraZeneca Puts Trials on Hold in UK
COVID-19 Vaccine Update: Covishield in Trial Phase, Adar and Natasha Poonawalla Meet Oxford University Professor Adrian Hill, Say ‘Super Excited for Next Few Months’
Arvind Kejriwal Allows RT-PCR COVID-19 Tests Without Prescription In Delhi, Vaccine ‘Sputnik V’ To Be Tested In India, Says Russian Media
COVID-19 Vaccine Update: Clinical Trials of Oxford's Covishield Will Continue in India, Says Serum Institute of India After AstraZeneca Puts Trials on Hold in UK
COVID-19 Vaccine Update: Covishield in Trial Phase, Adar and Natasha Poonawalla Meet Oxford University Professor Adrian Hill, Say ‘Super Excited for Next Few Months’
COVID-19 Vaccine: ‘Covishield’ To Be Available In 73 Days? Serum Institute Of India Busts Fake News, Calls Such Reports False
COVID-19 Vaccine Covishield, Developed by Oxford University-AstraZeneca, Faces Ire of Muslim, Christian Clerics in Australia Over Use of Fetal Cells
COVID-19 Vaccines in India Update: Bharat Biotech, Zydus Cadila in Phase 2 Trials, Oxford Candidate in Phase 3
COVID-19 Vaccine: ‘Covishield’ To Be Available In 73 Days? Serum Institute Of India Busts Fake News, Calls Such Reports False
COVID-19 Vaccine Covishield, Developed by Oxford University-AstraZeneca, Faces Ire of Muslim, Christian Clerics in Australia Over Use of Fetal Cells
COVID-19 Vaccines in India Update: Bharat Biotech, Zydus Cadila in Phase 2 Trials, Oxford Candidate in Phase 3
COVID-19 Vaccine Update: Phase II Trial of Oxford Coronavirus Vaccine Candidate to Begin in PGI Chandigarh
COVID-Vaccine Trials in India: Adar Poonawalla, CEO of Serum Institute of India, Urges Media to Refrain From Reporting on Interim Data About Patients on SII-Covishield Clinical Trials
Google Trends
